Prostate
Cancer Antigen 3
|
|
|
|
PROGRESSION-FREE
SURVIVAL
|
|
.
|
Hegde
JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR,
Kishan AU.
Prostate
Cancer Antigen 3 (PCA3) Score Does Not Predict for Adverse
Pathologic Features at Radical Prostatectomy or for
Progression-Free Survival in Clinically-Localized, Intermediate-
and High-Risk Prostate Cancer.
Urology.
2017 May 25. pii: S0090-4295(17)30565-4. doi:
10.1016/j.urology.2017.05.028. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
[-2]proPSA
(p2PSA)
|
|
|
|
CANCER
DETECTION
|
|
.
|
Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikeeva E, Fossati
N, Larcher A, Dell'Oglio P, Mistretta F, Buffi N, Guazzoni G,
Lazzeri M.
Clinical use of [-2]proPSA (p2PSA) and its
derivatives (%p2PSA and Prostate Health Index) for the detection
of prostate cancer: a review of the literature.
Korean J
Urol. 2014 Jul;55(7):436-45. doi: 10.4111/kju.2014.55.7.436. Epub
2014 Jul 11.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T,
Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B,
Le Corvoisier P, Alberola Bou J, Esquena Fernández S,
Graefen M, Guazzoni G.
Serum isoform [-2]proPSA
derivatives significantly improve prediction of prostate cancer at
initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric
European study.
Eur
Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011.
Epub 2013 Jan 24.
Source
| Full
text |
Similar
articles
|
|
|
BIOCHEMICAL
RECURRENCE
|
|
.
|
Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V,
Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari
M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi N.
[-2]proPSA
for predicting biochemical recurrence of prostate cancer earlier
than total PSA after radical prostatectomy: an observational
prospective cohort study.
Minerva Urol Nefrol. 2019 Jan
28. doi: 10.23736/S0393-2249.19.03279-X. [Epub ahead of print]
Source
|
Abstract
|
Similar
articles
|
|
|
.
|
Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T,
de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou
Redorta J, Graefen M, Guazzoni G, Lazzeri M.
Preoperative
Prostate-specific Antigen Isoform p2PSA and Its Derivatives,
%p2PSA and Prostate Health Index, Predict Pathologic Outcomes in
Patients Undergoing Radical Prostatectomy for Prostate Cancer:
Results from a Multicentric European Prospective Study.
Eur
Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034.
Epub 2014 Aug 16.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni
V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P,
Montorsi F.
Preoperative prostate-specific antigen
isoform p2PSA and its derivatives, %p2PSA and prostate health
index, predict pathologic outcomes in patients undergoing radical
prostatectomy for prostate cancer.
Eur Urol. 2012
Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov
4.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Huang YQ, Sun T, Zhong WD, Wu CL.
Clinical performance of
serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and
management of prostate cancer.
Am J Clin Exp Urol. 2014
Dec 25;2(4):343-50. eCollection 2014.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Lazzeri, M., Lughezzani, G., Larcher, A., Lista, G., Gadda, G. M.,
Scattoni, V., … Guazzoni, G.
Reply
to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B.
Boustead’s Letter to the Editor re: Giorgio Guazzoni,
Massimo Lazzeri, Luciano Nava, et al. Preoperative
Prostate-Specific Antigen Isoform p2PSA and Its Derivatives,
%p2PSA and Prostate Health Index, Predict Pathologic Outcomes in
Patients Undergoing Radical Prostatectomy for Prostate Cancer. Eur
Urol 2012;61:455–66. European Urology, 62(1), e16–e17.
Eur
Urol. 2012 Jul;62(1):author reply e16-7. doi:
10.1016/j.eururo.2012.04.029. Epub 2012 Apr 17.
Source
| Full
text |
Similar
articles
Referring
to: Tadtayev S et al, Re: Giorgio Guazzoni, Massimo Lazzeri,
Luciano Nava, et al. Preoperative prostate-specific antigen
isoform p2PSA and its derivatives, %p2PSA and Prostate Health
Index, predict pathologic outcomes in patients undergoing radical
prostatectomy for prostate cancer. Eur Urol 2012;61:455-66. Eur
Urol. 2012 Jul;62(1):e14-5; doi: 10.1016/j.eururo.2012.04.030.
Epub 2012 Apr 17.
Source
,
Full
text
In
turn referring
to: Guazzoni G et al., Preoperative prostate-specific antigen
isoform p2PSA and its derivatives, %p2PSA and prostate health
index, predict pathologic outcomes in patients undergoing radical
prostatectomy for prostate cancer.
Eur Urol. 2012
Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov
4. Source
,
Full
text
|
|
|
.
|
Tadtayev S, McNicholas TA, Boustead GB.
Re:
Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al.
Preoperative prostate-specific antigen isoform p2PSA and its
derivatives, %p2PSA and Prostate Health Index, predict pathologic
outcomes in patients undergoing radical prostatectomy for prostate
cancer. Eur Urol 2012;61:455-66.
Eur
Urol. 2012 Jul;62(1):e14-5; author reply e16-7. doi:
10.1016/j.eururo.2012.04.030. Epub 2012 Apr 17.
Source
| Full
text |
Similar
articles
Referring
to: Guazzoni G et al., Preoperative prostate-specific antigen
isoform p2PSA and its derivatives, %p2PSA and prostate health
index, predict pathologic outcomes in patients undergoing radical
prostatectomy for prostate cancer.
Eur Urol. 2012
Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov
4. Source
,
Full
text
|
|
|
|
|
|
|